Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Issues And Trends In Healthcare Delivery System

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Genomic reconstruction of the Pakistani Roma reveals dual South Asian ancestry, medieval bottlenecks, and the early dispersal routes of the Romani people.

Human genomics·2026

Same journal

Ferroptosis-related TFRC: a potential therapeutic target in sepsis and regulatory effect of γ-Tocotrienol.

Human genomics·2026

Same journal

Ancestry specific polygenic risk score, dietary patterns, physical activity and incident type 2 diabetes.

Human genomics·2026

Same journal

Mutational spectrum of SLC26A4 and SLC26A5 associated with hereditary hearing loss in Moroccan families.

Human genomics·2026

Same journal

National genomic projects in Asia and Africa: a review.

Human genomics·2026

Same journal

Analysis of whole-exome sequencing data from nearly 10,000 Iranian individuals: identification of recessive mitochondrial disease variants and proposal of a population-specific carrier screening panel.

Human genomics·2026

Search research articles

Related Experiment Video

Updated: Feb 21, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Precision medicine at the crossroads.

Maynard V Olson^1,2

¹Department of Medicine, University of Washington, Seattle, Washington, 98195, USA. mvo@u.washington.edu.

|October 13, 2017

Summary

This summary is machine-generated.

Creating a robust precision medicine data resource requires overcoming significant obstacles. A proposed solution involves dynamic consent, where research subjects interact with researchers via trusted mediators, facilitating data sharing for personalized therapies.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Related Experiment Videos

Last Updated: Feb 21, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Area of Science:

Biomedical research
Genomics
Personalized medicine

Background:

Precision medicine aims to tailor therapies to individual patients based on molecular data.
A 2011 report recommended creating an "information commons" for biomedical research data.
Significant bioethical, institutional, economic, legal, and cultural barriers hinder data resource creation.

Purpose of the Study:

To review the rationale and obstacles for creating a precision medicine information commons.
To propose a path forward for establishing such a data resource.
To advocate for the creation of this commons as a central policy objective.

Main Methods:

Review of existing literature and reports on precision medicine data sharing.
Analysis of bioethical, institutional, economic, legal, and cultural obstacles.
Proposal of a dynamic consent model involving trusted mediators.

Main Results:

The creation of a robust pre-competitive data resource is essential for advancing precision medicine.
Existing obstacles can be addressed through innovative data governance models.
Dynamic consent offers a viable solution for managing sensitive human data.

Conclusions:

The proposed dynamic consent model, facilitated by trusted mediators, offers a superior approach to handling individual human data (phenotypes, genotypes, environmental exposures).
Overcoming obstacles to create an "information commons" should be a primary policy goal for realizing precision medicine.
Implementing this system will accelerate the development and application of targeted therapies.